



SATELLITE SYMPOSIUM SUPPORTED BY NOVARTIS

16:15 – 18:15

Hall 3

IMPROVING CLINICAL OUTCOMES IN CML: A CHANGING THERAPEUTIC LANDSCAPE

Chair: G Rosti (University of Bologna, Bologna, Italy)

16:15

■ **PATTERN OF PRACTICE QUESTION**

16:20

■ **EFFICACY OF SECOND GENERATION TKIS AS SECOND LINE THERAPY FOR CML**

O Ottmann (Johann Wolfgang Goethe University, Frankfurt, Germany)

16:40

■ **PATTERN OF PRACTICE QUESTION**

16:45

■ **BCR-ABL KINASE DOMAIN MUTATIONAL ANALYSIS: BIOLOGY OF IMATINIB RESISTANCE**

S Soverini (University of Bologna, Bologna, Italy)

17:00

■ **PATTERN OF PRACTICE QUESTION**

17:05

■ **CLINICAL RELEVANCE OF BCR-ABL MUTATIONS**

P Laneuville (McGill University, Montreal, Quebec, Canada)

17:20

■ **INTERACTIVE CLINICAL CASE: SECOND LINE THERAPY FOR CHRONIC PHASE CML: HOW SHOULD CLINICIANS CHOOSE THE BEST OPTION?**

F Giles (University of Texas, San Antonio, TX, USA)

17:45

■ **PATTERN OF PRACTICE QUESTION**

17:50

■ **NEWLY DIAGNOSED CML: CAN WE IMPROVE UPON RESULTS ACHIEVED WITH IMATINIB?**

G Rosti (University of Bologna, Bologna, Italy)

18:10

■ **CLOSING REMARKS**

18:15

■ **ADJOURN**